Relmada Therapeutics, Inc. — Form 10-K Summary
Reporting period: Fiscal year ended June 30, 2015. Although the request identifies 2014 Q4, this filing is a 2015 fiscal-year 10-K; it does not provide separate fourth-quarter financial results. The company is a clinical-stage biopharmaceutical developer with no approved products or product revenue.
Financial performance and position
| Metric | FY ended June 30, 2015 | Prior comparable period |
|---|---|---|
| Revenue | None | None |
| Research and development | $7.87 million | $5.38 million |
| General and administrative | $9.23 million | $13.10 million |
| Operating loss | $17.10 million | $18.48 million |
| Net loss | $20.80 million | $28.07 million |
| Net loss per share, basic and diluted | $2.09 | $18.89 |
| Cash used in operating activities | $16.23 million | $7.21 million |
Prior comparable period is the unaudited twelve months ended June 30, 2014, presented because the company changed its fiscal year-end. The audited six-month transition period is not directly comparable.
- Research and development spending rose with increased clinical activity. General and administrative expense declined primarily because the prior comparable period included substantial noncash stock compensation.
- The company recorded a $3.71 million noncash loss from changes in derivative fair value, versus $8.97 million in the prior comparable period. This accounting charge is tied to warrants and may fluctuate with share price and valuation assumptions.
- At June 30, 2015, cash and cash equivalents were $22.47 million, down from $25.56 million a year earlier. Current assets were $23.97 million and current liabilities $15.58 million, including $14.00 million of warrant-related derivative liabilities. Stockholders’ equity was $8.81 million.
- Note payable was $263,752. Total contractual obligations were $6.80 million, including $3.99 million of research and development commitments and $2.55 million of lease obligations. Approximately $4.52 million was due within one year.
- Accumulated deficit was $76.12 million. The company reported no income tax provision and maintained a full valuation allowance against deferred tax assets.
Business progress and material changes
- d-Methadone (REL-1017): The Phase I single-ascending-dose study was completed in June 2015, with no dose-limiting side effects reported in the initial cohorts. Health Canada issued a no-objection letter for a multiple-ascending-dose study in August 2015. The studies are intended to inform a potential Phase II proof-of-concept study.
- LevoCap ER (REL-1015): The company continued manufacturing scale-up and preparation for a planned Phase III program, including selection of a final formulation and GMP batches. It planned to seek FDA discussion of the regulatory and clinical plan; pivotal development had not yet begun.
- BuTab (REL-1028): Health Canada approved a Phase I pharmacokinetic study in healthy volunteers, reported as ongoing. The candidate is an oral modified-release buprenorphine formulation for chronic pain and opioid dependence.
- MepiGel (REL-1021): The company selected topical formulations for planned Phase I testing. FDA orphan-drug designations cover painful HIV-associated neuropathy and postherpetic neuralgia; these designations do not constitute marketing approval.
- The company issued 2.03 million A warrants during the year, receiving net proceeds of approximately $13.42 million. It also completed a one-for-five reverse stock split on August 12, 2015, after year-end, and reported a September 2015 patent issuance covering its SECUREL platform and LevoCap ER.
Outlook, risks and unusual items
- Management expected the June 30, 2015 cash balance to fund operations through the end of calendar 2016, while also stating that additional capital would be needed to continue development and should be raised in the second half of 2015. No formal revenue or earnings guidance was provided.
- The company expects continued operating losses and has no product revenue, sales infrastructure, or approved products. Its ability to continue clinical development depends on raising capital; financing may be unavailable or dilutive, and management warned that programs could be delayed, reduced, or discontinued if funding is insufficient.
- Principal risks include early-stage clinical and regulatory uncertainty, opioid-control requirements and DEA quotas, reliance on contract manufacturers and a single levorphanol API source, dependence on collaborators for eventual commercialization, competition, reimbursement uncertainty, and product-liability exposure. The filing says the company carried clinical-trial insurance but no product-liability insurance.
- A former officer brought a lawsuit alleging breach of contract and other claims; the company moved to dismiss and management believed an adverse outcome would not materially affect operations or financial position, while acknowledging litigation uncertainty.
- Related-party arrangements merit attention: an advisory firm affiliated with board chair Sandesh Seth received warrants to purchase 1,731,157 shares at $0.001 and a monthly fee; that arrangement ended June 30, 2015. A subsequent consulting agreement with Mr. Seth provided for $12,500 per month.
- The company reported effective disclosure controls and effective internal control over financial reporting; its auditor issued unqualified opinions on the financial statements and internal controls. Separately, the filing describes a potential Securities Act compliance issue involving a July 2014 press release and possible investor rescission rights.
Investor verification priorities
- Confirm the actual timing, terms, and dilution from any post-year-end financing, and assess whether cash runway assumptions remain achievable against clinical costs and commitments.
- Verify the status, enrollment, safety findings, and next milestones for the d-Methadone and BuTab studies, and reconcile the filing’s pipeline descriptions with a risk-factor statement that says there were no ongoing trials.
- Assess the regulatory path and funding required for LevoCap ER pivotal trials, including U.S. manufacturing readiness and the availability of commercial-grade levorphanol supply.
- Review warrant terms, derivative-liability valuation assumptions, potential share dilution, and the effects of the reverse split and subsequent patent issuance.
- Check developments in the former-officer litigation and the potential consequences of the disclosed Securities Act issue, as well as the terms and governance of related-party arrangements.